>The study set dual primary endpoints, including overall survival (OS) and progression-free survival (PFS) assessed by the blinded independent central review committee (BICR) according to RECIST v1. 1 .
The latest data on the treatment of R/R CLL/SLL with Bcl-2 inhibitors by Ascent Pharmaceuticals: ORR reaches 80%
Time of Update: 2021-06-22
partial remission (PR) in a number of test patients with other tumors . >Dr. Asher Chanan-Khan, professor of medicine at the Mayo Clinic in the United States and the global
Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody
Time of Update: 2021-06-22
Recently, Hansi Biotechnology announced that it has initiated a phase 2 clinical study of the anti-CD47/PD-1 bispecific antibody HX009 injection, and plans to develop the treatment of advanced solid tumors .
The complete remission rate of refractory patients exceeds 30% CD37 targeted ADC combination Phase 2...
Time of Update: 2021-06-22
of relapsed/refractory (R/R) diffuse Positive results were obtained in a phase 2 clinical trial of large B-cell lymphoma (DLBCL) . The trial results showed that the combination therapy achieved
Courier treatment of Alzheimer's disease, Phase 2 clinical results of innovative tau protein vaccine published
Time of Update: 2021-06-22
▎The content team editor of WuXi AppTec today, Axon Neuroscience announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD
Type 1 and 2 diabetes have ushered in new progress: support for approval, introduction of authorization...
Time of Update: 2021-06-22
2. International clinical practice guidelines are released: SGLT-2 inhibitors or GLP-1 receptor agonists are recommended for adult patients with type 2 diabetes
Lymphocytic Leukemia: 7-year follow-up of the RESONATE-2 study
Time of Update: 2021-06-22
Today I will mainly introduce an abstract on EHA in 2021: First-line treatment of Ibrutinib in patients with chronic lymphocytic leukemia: 7-year follow-up of the RESONATE-2 study .
Express more than 2 billion U.S. dollars to help develop anti-TIGIT antibodies, GSK adds a new generation of cancer immunotherapy
Time of Update: 2021-06-22
▲ GSK's R&D layout for the CD226 signaling pathway (picture source: reference [2]) EOS-448 developed by iTeos is an anti-TIGIT monoclonal antibody with multiple mechanisms of action .
Zejing Pharmaceutical's JAK inhibitor phase 2 clinical success
Time of Update: 2021-06-22
On June 11, Zejing Pharmaceutical issued an announcement stating that its Phase 2 clinical study (ZGJAK002) for the treatment of intermediate and high-risk myelofibrosis with its new
%, and the phase 2 clinical results of the CD37-targeted ADC combination are positive
Time of Update: 2021-06-22
/refractory Positive results were obtained in the Phase 2 clinical trial of R/R diffuse large B-cell lymphoma (DLBCL) . The trial results showed that the combination therapy
Synthekine new generation IL-2 mutant
Time of Update: 2021-06-22
STK-012 avoids acting on NK cells and Naive T cells to avoid toxicity, and targeting antigens to activate CD8 T cells can more specifically enhance anti-tumor activity .
1. Type 2 diabetes has ushered in new progress: support for approval, guideline recommendation, introduction authorization...
Time of Update: 2021-06-22
> 2. International clinical practice guidelines are released: Recommend SGLT-2 inhibitors or GLP-1 receptor agonists for adult type 2 diabetes patients with type 2 diabetes (T2D) as the most common metabolic disease, in the past 50 years
2 billion large varieties!
Time of Update: 2021-06-22
com, China's public medical institutions terminal competition patternPreviously reviewed companies for Lansoprazole for injectionSource: Mi Nei Net Consistency Evaluation DatabaseLansoprazole injection has been included in the fifth batch of centralized procurement, and the bid will be opened on June 23.
Ascent Pharma's Bcl-2 inhibitor APG-2575 obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-06-22
The study is a global multi-center, open, phase Ib/II clinical study, which aims to evaluate the progress of APG-2575 monotherapy in patients with advanced solid tumors, or in combination with CDK4/6 inhibitor palbociclib after treatment with CDK4/6 inhibitors.
Phase 2 clinical results of innovative tau protein vaccine for the treatment of Alzheimer's disease published
Time of Update: 2021-06-22
Today, Axon Neuroscience announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-published Nature Aging .
Inspection Information for Food Safety During the Dragon Boat Festival (Phase 2)
Time of Update: 2021-06-22
According to "People's Republic of China Food Safety Law requirements," Xiaogan City
Over 2 billion U.S. dollars to develop anti-TIGIT antibody GSK to add to the layout of a new generation of cancer immunotherapy
Time of Update: 2021-06-22
▲ GSK's R&D layout for the CD226 signal path (picture source: reference [2]) EOS-448 developed by iTeos is an anti-TIGIT monoclonal antibody with multiple mechanisms of action .
